Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 7/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.52 |
| ▸ | CDK1 | P06493 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | CDK9 | P50750 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | CDK7 | P50613 | 2/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNH | P51946 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 6/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973298 | 0.91 | JAK3 (0.56) | AURKAAURKBCDK2CCNA2CDK1 | |
| SCHEMBL4973563 | 0.89 | CDK2 (0.53) | AURKAAURKBCDK2CCNA2CDK1 | |
| SCHEMBL5621484 | 0.88 | AURKA (0.58) | AURKAAURKBCDK2CCNA2CDK1 | |
| SCHEMBL4971328 | 0.88 | SYK (0.61) | AURKAAURKBCDK2CCNA2CDK1 | |
| SCHEMBL4973572 | 0.85 | AURKA (0.55) | AURKAAURKBCDK2CCNA2CDK1 | |
| SCHEMBL4972327 | 0.85 | AURKA (0.55) | AURKAAURKBCDK2CCNA2CDK1 | |
| SCHEMBL3999767 | 0.83 | AURKA (0.55) | AURKAAURKBCDK2CCNA2CDK1 | |
| SCHEMBL4971338 | 0.83 | AURKA (0.55) | AURKAAURKBCDK2CCNA2CDK1 | |
| SCHEMBL4975370 | 0.82 | AURKA (0.56) | AURKAAURKBCDK2CCNA2CDK1 | |
| SCHEMBL3998901 | 0.82 | AURKA (0.58) | AURKAAURKBCDK2CCNA2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991532-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | claimed |
| US-8962643-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | claimed |
| EP-1991532-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2007098507-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
| EP-1991532-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9481654-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150158824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-8962643-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-1991532-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007098507-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | AURKA 3449/4885AURKB 3015/4885CDK2 986/4885 |
| US-20150158824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | AURKA 751/4885AURKB 461/4885CDK2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.